FDA Adverse Event Reports by Hims & Hers – Semaglutide and Tirzepatide (Jan–Mar 2025)

FDA Adverse Event Reports by Hims & Hers – Semaglutide and Tirzepatide (Jan–Mar 2025)

Regular price $69.00 USD
Regular price Sale price $69.00 USD
Sale Sold out
Original Request: Please provide me with data on the adverse events reported to the FDA by Hims & Hers Health for compounded semaglutide and/or tirzepatide injections between January 1, 2025 and March 19, 2025.
Tags: Pharma, Adverse Event, 2025

NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

View full details